Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Renhe Pharmacy Co's share price for the quarter that ended in Jun. 2026 was ¥5.09. Renhe Pharmacy Co's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 1,400 Mil. Therefore, Renhe Pharmacy Co's market cap for the quarter that ended in Jun. 2026 was ¥7,126 Mil.
Renhe Pharmacy Co's quarterly market cap
increased
from Dec. 2025 (¥7,910 Mil) to Mar. 2026 (¥8,036 Mil) but then
declined
from Mar. 2026 (¥8,036 Mil) to Jun. 2026 (¥7,126 Mil).
Renhe Pharmacy Co's annual market cap
declined
from Dec. 2023 (¥9,282 Mil) to Dec. 2024 (¥8,064 Mil) and
declined
from Dec. 2024 (¥8,064 Mil) to Dec. 2025 (¥7,910 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Renhe Pharmacy Co's Enterprise Value for Today is ¥4,029 Mil.
Renhe Pharmacy Co (SZSE:000650) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Renhe Pharmacy Co Market Cap Related Terms
Renhe Pharmacy Co Market Cap Historical Data
* Premium members only.
The historical data trend for Renhe Pharmacy Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Renhe Pharmacy Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renhe Pharmacy Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Renhe Pharmacy Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Renhe Pharmacy Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Renhe Pharmacy Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renhe Pharmacy Co (SZSE:000650) has a Market Cap of ¥7,518 Mil as of Sep. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Renhe Pharmacy Co and its competitors. According to the industry distribution chart, Renhe Pharmacy Co ranks #242 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 23.7%.
Is Renhe Pharmacy Co's Market Cap too high?
Renhe Pharmacy Co's current Market Cap is ¥7,518 Mil. Based on the distribution chart, Renhe Pharmacy Co ranks #242 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Renhe Pharmacy Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Renhe Pharmacy Co's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Renhe Pharmacy Co ranks #242 out of 1023 companies for Market Cap. This places Renhe Pharmacy Co in the top 24% of its industry — outperforming the majority of peers. The industry median Market Cap is 235.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 235.32, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Renhe Pharmacy Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 235.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renhe Pharmacy Co's current Market Cap is ¥7,518 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renhe Pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Renhe Pharmacy Co (SZSE:000650) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.07, compared to a current price of ¥5.37 — trading 5.9% above its estimated fair value. The current Market Cap is ¥7,518 Mil. Renhe Pharmacy Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Renhe Pharmacy Co (SZSE:000650), the current Market Cap is ¥7,518 Mil as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renhe Pharmacy Co (SZSE:000650) Overvalued in 2026?
Based on GuruFocus' analysis, Renhe Pharmacy Co stock appears to be overvalued.
The current stock price of ¥5.37 is trading 5.9% above its estimated GF Value™ of ¥5.07.
GuruFocus considers Renhe Pharmacy Co to be Fairly Valued.
Key valuation signals for SZSE:000650:
Market Cap: ¥7,518 Mil
GF Value™: ¥5.07 vs. price of ¥5.37 (5.9% above fair value)
No single metric tells the full story. See the SZSE:000650 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renhe Pharmacy Co Ltd is a China-based company engaged in the production and sale of Chinese and Western medicines, raw materials, and health-related products, including oral solid dosage forms, oral liquid dosage forms, large-volume injections, small-volume injections, external washes, liniments, suppositories, ointments, and other dosage forms of pharmaceuticals and health-related products. The company's main products include: Renhe Kelike, Youkadan series, Fuyanjie series, Da Huo Luo capsules, Shanliang eye drops, Qinghuo capsules, and Zhengwei capsules.
83GF Score
Get the complete analysis for SZSE:000650
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:000650 has been successfully added to your 
